Trial Profile
A Phase I, Open-label Study to Assess the Pharmacokinetics of KY1005 After Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Dec 2020
Price :
$35
*
At a glance
- Drugs Amlitelimab (Primary) ; Amlitelimab (Primary)
- Indications Atopic dermatitis; Autoimmune disorders; Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors Kymab
- 17 Dec 2020 Status changed from recruiting to completed.
- 23 Jul 2020 Status changed from not yet recruiting to recruiting.
- 06 Aug 2018 New trial record